Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: The European Organisation for Research and Treatment of Cancer genito-urinary tract cancer group (EORTC 30951)

Journal of Clinical Oncology

Volumn 23, Issue 18, 2005, Pages 4172-4178

  Aass, Nina ^a   De Mulder, Pieter H M ^a   Mickisch, Gerald H J ^a   Mulders, Peter ^a   Van Oosterom, Allan T ^a   Van Poppel, Hein ^a   Fossa, Sophie D ^a   De Prijck, Linda ^a   Sylvester, Richard J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ISOTRETINOIN; RECOMBINANT ALPHA2A INTERFERON; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG WITHDRAWAL; DRY NOSE; DRY SKIN; FATIGUE; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; LETHARGY; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT OUTCOME; XEROSTOMIA; DISEASE FREE SURVIVAL; KIDNEY TUMOR; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON ALFA-2A; ISOTRETINOIN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 23044461230     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.114     Document Type: Article

References (26)

1. Harris DT: Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 10:422-430, 1983
2. Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22:42-60, 1995
3. Amato RJ: Chemotherapy for renal cell carcinoma. Semin Oncol 27:177-186, 2000
4. Fossa SD: Interferon in metastatic renal cell carcinoma. Semin Oncol 27:187-193, 2000
5. Margolin KA: Interleukin-2 in the treatment of renal cancer. Semin Oncol 27:194-203, 2000
6. Martel CL, Lara PN: Renal cell carcinoma: Current status and future directions. Crit Rev Oncol Hematol 45:177-190, 2003
7. Yang JC, Sherry RM, Steinberg SM, et al: Randomized study of high-dose and low-dose Interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127-3132, 2003
8. Medical Research Council: Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial-Medical Research Council Renal Cancer Collaborators. Lancet 353:14-17, 1999
9. Pyrhonen S, Salminen E, Ruutu M, et al: Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17:2859-2867, 1999
10. Cameron RB, McIntosh JK, Rosenberg SA: Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 48:5810-5817, 1988
11. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie. N Engl J Med 338:1272-1278, 1998
12. Bollag W: Retinoids and interferon: A new promising combination? Br J Haematol 79:87-91, 1991 (suppl 1)
13. Frey JR, Peck R, Bollag W: Antiproliferative activity of retinoids, interferon alpha and their combination in five human transformed cell lines. Cancer Lett 57:223-227, 1991
14. Motzer RJ, Schwartz L, Law TM, et al: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13:1950-1957, 1995
15. Lippman SM, Parkinson DR, Itri LM, et al: 13-cis-retinoic acid and interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235-241, 1992
16. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al: 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 85:499-500, 1993
17. Fossa SD, Mickisch GHJ, De Mulder P, et al: Interferon alpha-2a with or without 13-cis retinoic acid in patients with progressive measurable metastatic renal cell carcinoma: Results of a randomized phase II study (EORTC 30951). Cancer 101:533-540, 2004
18. Jones M, Philip T, Palmer P, et al: The impact of interleukin-2 on survival in renal cancer: A multivariate analysis. Cancer Biother 8:275-288, 1993
19. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996
20. Motzer RJ, Murphy BA, Bacik J, et al: Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972-2980, 2000
21. Atzpodien J, Kirchner H, Jonas U, et al: Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A prospective randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188-1194, 2004
22. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999
23. Flanigan RC, Mickisch G, Sylvester R, et al: Cytoreductive nephrectomy in patients with metastatic renal cancer: Combined analysis. J Urol 171:1071-1076, 2004
24. Motzer RJ, Mazumdar M, Bacik J, et al: Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928-1935, 2000
25. Wong M, Goldstein D, Woo H, et al: Alpha-interferon 2a and 1 3-cis-retinoic acid for the treatment of metastatic renal cell carcinoma. Intern Med J 32:158-162, 2002
26. Mross K, Scheulen ME, Manegold C, et al: Phase II study with interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell carcinoma: A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society. Ontologie 22:412-415, 1999